NasdaqGS:IDXXMedical Equipment
Should Strong 2025 Results and 2026 Outlook for CAG Diagnostics Recurring Revenue Require Action From IDEXX Laboratories (IDXX) Investors?
IDEXX Laboratories recently reported past fourth-quarter 2025 results showing higher sales of US$1,090.58 million and increased net income of US$248.19 million, alongside initial 2026 guidance calling for US$4.63–US$4.72 billion in revenue and earnings per share of US$14.29–US$14.80.
Beyond the headline figures, management highlighted that growth is being led by CAG Diagnostics recurring revenue and supported by newer veterinary tests that have exceeded utilization expectations, underscoring...